SCHEMBL4468614

SCHEMBL4468614

CCOC(=O)c1cc(Cl)ncc1N

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
HSD17B10 Q99714 1/20 0.49
TSHR P16473 2/20 0.47
HSP90AA1 P07900 1/20 0.47
HTT P42858 1/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 3/20 0.46
KDM4E B2RXH2 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
CHEK2 O96017 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
CSNK1D P48730 1/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31437304 1.00 ALDH1A1 (0.49) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL29374466 0.88 HSP90AA1 (0.50) ALDH1A1MEN1KMT2AHSD17B10HSP90AA1
SCHEMBL2445600 0.88 HSP90AA1 (0.50) ALDH1A1MEN1KMT2AHSD17B10HSP90AA1
SCHEMBL3516119 0.85 BAZ2B (0.49) ALDH1A1MEN1KMT2ATSHRHSP90AA1
SCHEMBL2237761 0.84 TSHR (0.46) ALDH1A1MEN1KMT2ATSHRHSP90AA1
SCHEMBL6134191 0.84 CYP4F2 (0.51) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL31368185 0.84 CYP4F2 (0.51) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL24341947 0.83 KMT2A (0.46) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL9400503 0.83 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL29557951 0.83 KMT2A (0.46) ALDH1A1MEN1KMT2AHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4105213-B1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME PHAROS IBIO CO LTD (KR) 2026-04-15 EP disclosed
US-20230120564-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-04-20 US disclosed
EP-4105213-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME Korea Institute of Science and Technology (KR) 2022-12-21 EP disclosed
EP-3939588-A1 USES OF PHOSPHODIESTERASE INHIBITORS Transthera Sciences (Nanjing), Inc. (CN) 2022-01-19 EP disclosed
EP-3915992-A1 PDE9 INHIBITOR AND USE THEREOF Transthera Sciences (Nanjing), Inc. (CN) 2021-12-01 EP disclosed
WO-2021145521-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME 한국과학기술연구원 2021-07-22 WO disclosed
WO-2021145521-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME 한국과학기술연구원 2021-07-22 WO disclosed
EP-2900666-B1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2020-11-04 EP disclosed
EP-2900666-B1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2020-11-04 EP disclosed
WO-2020182076-A1 USES OF PHOSPHODIESTERASE INHIBITORS 南京药捷安康生物科技有限公司 2020-09-17 WO disclosed
WO-2014052699-A9 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C IGNYTA, INC. (US) 2015-07-16 WO disclosed
EP-1717230-B1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE MSD KK (JP) 2014-08-06 EP disclosed
US-20140113882-A1 Azaquinazoline Inhibitors of Atypical Protein Kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-04-24 US disclosed
US-8268842-B2 Fused ring 4-oxopyrimidine derivative MSD K.K. (JP) 2012-09-18 US disclosed
CN-1918128-B fused ring 4-oxo-pyrimidine derivatives BANYU PHARMA CO LTD 2011-01-26 CN disclosed
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-08-20 US disclosed
US-7521455-B2 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO. LTD. (JP) 2009-04-21 US disclosed
CN-1918128-A Fused ring 4-oxo-pyrimidine derivatives BANYU PHARMA CO LTD (JP) 2007-02-21 CN disclosed
EP-1717230-A1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 EP disclosed
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113882-A1 Azaquinazoline Inhibitors of Atypical Protein Kinase C PRKCQ, PRKCZ, PRKCE ALDH1A1 4626/4885MEN1 3299/4885KMT2A 1134/4885
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 ALDH1A1 1717/4885MEN1 2904/4885KMT2A 528/4885
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 ALDH1A1 1717/4885MEN1 2904/4885KMT2A 528/4885
US-20230120564-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME DPYD, WEE1, CDK4 ALDH1A1 1068/4885MEN1 2010/4885KMT2A 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.